Week 52 Subgroup Efficacy Analyses of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People With Multidrug-Resistant HIV (CAPELLA Study)

Press/Media: Press / Media

Period	Oct 28 2022

Media coverage

Title	Week 52 Subgroup Efficacy Analyses of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People With Multidrug-Resistant HIV (CAPELLA Study)
Media name/outlet	National AIDS Treatment Advocacy Project
Country/Territory	United States
Date	10/28/22
URL	ct.moreover.com/?a=49103273025&p=1gw&v=1&x=SHt_eeRvxJBxTiOMeXM-Nw
Persons	Hui Wang